1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

$31m in new funds to help Cebix progress novel peripheral neuropathy candidate

 
• By Mandy Jackson

San Diego-based Cebix has closed a $30.9 million Series B venture capital financing round to fund Phase IIb development for the company's C-peptide replacement therapy Ersatta, which may become the first disease-modifying treatment for peripheral neuropathy in type 1 diabetes patients.

San Diego-based Cebix has closed a $30.9 million Series B venture capital financing round to fund Phase IIb development for the company's C-peptide replacement therapy Ersatta, which may become the first disease-modifying treatment for peripheral neuropathy in type 1 diabetes patients.

Several companies have sought regulatory approvals for drugs that reduce the pain of diabetic peripheral neuropathy, rather than develop therapies that prevent or slow the progression of long-term complications associated with type 1 diabetes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

More from Therapeutic Category